Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Cassava Sciences Inc (SAVA) since 2018 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Cassava Sciences Inc. Table 2 shows the detailed insider transactions. This company's CIK number is 1069530.
Total stock buying since 2018: $10,536,850.
Total stock sales since 2018: $663,944.
Total stock option exercises since 2018: $15,470,564.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 258,838 | $580,213 | 0 | $0 | 0 | $0 |
| 2024 | 0 | $0 | 4,000 | $15,480 | 248,085 | $5,457,870 |
| 2023 | 137,318 | $3,124,249 | 0 | $0 | 111,423 | $1,903,000 |
| 2022 | 141,159 | $3,040,197 | 0 | $0 | 185,912 | $2,961,659 |
| 2021 | 0 | $0 | 0 | $0 | 101,788 | $5,148,035 |
| 2020 | 272,000 | $1,995,704 | 0 | $0 | 0 | $0 |
| 2019 | 627,899 | $1,693,439 | 0 | $0 | 0 | $0 |
| 2018 | 100,000 | $103,048 | 1,768,660 | $648,464 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-09 | 258,838 | $580,213 | 0 | $0 | 0 | $0 |
| 2024-11 | 0 | $0 | 4,000 | $15,480 | 0 | $0 |
| 2024-04 | 0 | $0 | 0 | $0 | 248,085 | $5,457,870 |
| 2023-08 | 48,477 | $831,427 | 0 | $0 | 0 | $0 |
| 2023-05 | 0 | $0 | 0 | $0 | 104,281 | $1,773,516 |
| 2023-03 | 88,841 | $2,292,822 | 0 | $0 | 7,142 | $129,484 |
| 2022-10 | 0 | $0 | 0 | $0 | 28,128 | $26,721 |
| 2022-09 | 0 | $0 | 0 | $0 | 2,802 | $66,099 |
| 2022-08 | 141,159 | $3,040,197 | 0 | $0 | 0 | $0 |
| 2022-06 | 0 | $0 | 0 | $0 | 65,368 | $1,528,303 |
| 2022-05 | 0 | $0 | 0 | $0 | 28,014 | $654,967 |
| 2022-04 | 0 | $0 | 0 | $0 | 49,460 | $426,839 |
| 2022-03 | 0 | $0 | 0 | $0 | 12,140 | $258,730 |
| 2021-09 | 0 | $0 | 0 | $0 | 2,801 | $76,663 |
| 2021-07 | 0 | $0 | 0 | $0 | 2,801 | $56,664 |
| 2021-05 | 0 | $0 | 0 | $0 | 56,030 | $3,000,406 |
| 2021-03 | 0 | $0 | 0 | $0 | 40,156 | $2,014,302 |
| 2020-09 | 272,000 | $1,995,704 | 0 | $0 | 0 | $0 |
| 2019-12 | 617,899 | $1,682,839 | 0 | $0 | 0 | $0 |
| 2019-05 | 10,000 | $10,600 | 0 | $0 | 0 | $0 |
| 2018-10 | 0 | $0 | 512,660 | $224,032 | 0 | $0 |
| 2018-09 | 100,000 | $103,048 | 0 | $0 | 0 | $0 |
| 2018-08 | 0 | $0 | 1,256,000 | $424,432 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-09-30 | Cook Robert Christopher (Chief Operating & Legal Office) | Buy | 13,725 | 2.91 | 39,939 |
| 2025-09-22 | Barry Richard (President & CEO) | Buy | 7,172 | 2.28 | 16,352 |
| 2025-09-19 | Barry Richard (President & CEO) | Buy | 47,308 | 2.27 | 107,389 |
| 2025-09-18 | Barry Richard (President & CEO) | Buy | 190,633 | 2.19 | 416,533 |
| 2024-11-29 | Kupiec James William (Chief Medical Officer) | Sale | 4,000 | 3.87 | 15,480 |
| 2024-04-26 | Robertson Sanford (Director) | Option Ex | 69,000 | 22.00 | 1,518,000 |
| 2024-04-23 | Barry Richard (Director) | Option Ex | 176,085 | 22.00 | 3,873,870 |
| 2024-04-18 | Kupiec James William (Chief Medical Officer) | Option Ex | 1,500 | 22.00 | 33,000 |
| 2024-04-17 | Schoen Eric (Chief Financial Officer) | Option Ex | 1,500 | 22.00 | 33,000 |
| 2023-08-23 | Robertson Sanford (Director) | Buy | 30,000 | 17.45 | 523,500 |
| 2023-08-22 | Barry Richard (Director) | Buy | 16,571 | 16.65 | 275,907 |
| 2023-08-21 | Barry Richard (Director) | Buy | 1,906 | 16.80 | 32,020 |
| 2023-05-24 | Barbier Remi (President and CEO) | Option Ex | 85,713 | 16.87 | 1,445,978 |
| 2023-05-10 | Robertson Sanford (Director) | Option Ex | 9,284 | 17.64 | 163,769 |
| 2023-05-01 | Gussin Robert Z (Director) | Option Ex | 9,284 | 17.64 | 163,769 |
| 2023-03-07 | Barry Richard (Director) | Buy | 77,276 | 25.76 | 1,990,629 |
| 2023-03-07 | O Donnell Michael J (Director) | Option Ex | 7,142 | 18.13 | 129,484 |
| 2023-03-06 | Barry Richard (Director) | Buy | 11,565 | 26.13 | 302,193 |
| 2022-10-03 | Friedmann Nadav (Chief Medical Officer) | Option Ex | 18,752 | .95 | 17,814 |
| 2022-09-08 | Robertson Sanford (Director) | Option Ex | 2,802 | 23.59 | 66,099 |
| 2022-08-23 | Kupiec James William (Chief Clinical Dev. Officer) | Buy | 2,500 | 24.44 | 61,100 |
| 2022-08-23 | Barry Richard (Director) | Buy | 36,159 | 23.79 | 860,222 |
| 2022-08-12 | Schoen Eric (Chief Financial Officer) | Buy | 2,500 | 19.95 | 49,875 |
| 2022-08-12 | Robertson Sanford (Director) | Buy | 100,000 | 20.69 | 2,069,000 |
| 2022-06-06 | Barbier Remi (President and CEO) | Option Ex | 65,368 | 23.38 | 1,528,303 |
| 2022-05-27 | Friedmann Nadav (Chief Medical Officer) | Option Ex | 28,014 | 23.38 | 654,967 |
| 2022-04-25 | Barbier Remi (President and CEO) | Option Ex | 49,460 | 8.63 | 426,839 |
| 2022-03-29 | Gussin Robert Z (Director) | Option Ex | 7,470 | 21.95 | 163,929 |
| 2022-03-25 | Robertson Sanford (Director) | Option Ex | 4,670 | 20.30 | 94,801 |
| 2021-09-15 | Gussin Robert Z (Director) | Option Ex | 2,801 | 27.37 | 76,663 |
| 2021-07-20 | Barbier Remi (President and CEO) | Option Ex | 2,801 | 20.23 | 56,664 |
| 2021-05-27 | Barbier Remi (President and CEO) | Option Ex | 56,030 | 53.55 | 3,000,406 |
| 2021-03-30 | Robertson Sanford (Director) | Option Ex | 7,472 | 38.19 | 285,318 |
| 2021-03-17 | Friedmann Nadav (Chief Medical Officer) | Option Ex | 28,015 | 53.55 | 1,500,203 |
| 2021-03-16 | O Donnell Michael J (Director) | Option Ex | 4,669 | 49.00 | 228,781 |
| 2020-09-24 | Barbier Remi (President and CEO) | Buy | 10,000 | 9.59 | 95,900 |
| 2020-09-18 | Robertson Sanford (Director) | Buy | 36,281 | 8.92 | 323,626 |
| 2020-09-17 | Schoen Eric (Chief Financial Officer) | Buy | 12,000 | 7.04 | 84,420 |
| 2020-09-17 | Robertson Sanford (Director) | Buy | 213,719 | 6.98 | 1,491,758 |
| 2019-12-31 | Barbier Remi (President and CEO) | Buy | 100,000 | 5.53 | 553,000 |
| 2019-12-26 | Barbier Remi (President and CEO) | Buy | 10,000 | 4.15 | 41,500 |
| 2019-12-20 | Robertson Sanford (Director) | Buy | 423,788 | 2.20 | 932,333 |
| 2019-12-19 | Schoen Eric (Chief Financial Officer) | Buy | 5,300 | 1.88 | 9,964 |
| 2019-12-19 | Robertson Sanford (Director) | Buy | 76,212 | 1.86 | 141,754 |
| 2019-12-18 | Barbier Remi (President and CEO) | Buy | 2,599 | 1.65 | 4,288 |
| 2019-05-14 | Schoen Eric (Chief Financial Officer) | Buy | 10,000 | 1.06 | 10,600 |
| 2018-10-03 | Boyd Steven | Sale | 512,660 | .44 | 224,032 |
| 2018-09-27 | Robertson Sanford (Director) | Buy | 37,817 | 1.05 | 39,707 |
| 2018-09-26 | Robertson Sanford (Director) | Buy | 30,992 | 1.05 | 32,541 |
| 2018-09-25 | Robertson Sanford (Director) | Buy | 21,420 | 1.00 | 21,420 |
| 2018-09-24 | Robertson Sanford (Director) | Buy | 9,771 | .96 | 9,380 |
| 2018-08-20 | Boyd Steven | Sale | 8,000 | .30 | 2,416 |
| 2018-08-17 | Boyd Steven | Sale | 48,000 | .32 | 15,216 |
| 2018-08-16 | Boyd Steven | Sale | 1,200,000 | .34 | 406,800 |
Insider trading activities including stock purchases, stock sales, and option exercises of SAVA listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Cassava Sciences Inc (symbol SAVA, CIK number 1069530) see the Securities and Exchange Commission (SEC) website.